Neogenomics Inc reports results for the quarter ended in March - Earnings Summary

NeoGenomics

30/04/2024 15:13

* Neogenomics Inc  NEO.OQ  reported a quarterly adjusted
loss of 2
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -9
cents.  The mean expectation of thirteen analysts for the
quarter was for a loss of 5 cents per share. Wall Street
expected results to range from -11 cents to -2 cents per share.
    * Revenue rose 13.9% to $156.24 million from a year ago;
analysts
expected $149.89 million. 
    * Neogenomics Inc's reported EPS for the quarter was a loss
of 21
cents​.
    * The company reported a quarterly loss of $27.06 million.
    * Neogenomics Inc shares had fallen by 3.2% this quarter and
lost 5.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Neogenomics Inc
is $20.00 
This summary was machine generated from LSEG data April 30 at
02:12 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.05          -0.02          Beat
 Dec. 31 2023      -0.02          0.03           Beat
 Sep. 30 2023                     0.00           
 Jun. 30 2023      -0.11          -0.05          Beat